Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02707861 · ClinicalTrials.gov registry record · Phase 3
Ibalizumab Plus Optimized Background Regimen in Treatment-Experienced Patients With Multi-Drug Resistant HIV-1
A Phase 3 study, sponsored by TaiMed Biologics.
- Completed
- Registry status
- Phase 3
- Development phase
- 79
- Enrollment target
NCT02707861: Completed Phase 3 study, sponsored by TaiMed Biologics.
NCT02707861 is a Phase 3 study that has completed, run by TaiMed Biologics. The registered enrollment target is 79 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (90% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02707861, a Phase 3 study, has completed, sponsored by TaiMed Biologics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 79 participants
- Enrollment target
Study Summary
Ibalizumab is a monoclonal antibody that works by blocking HIV entry into the immune system cells (CD4+ or T-cells) the virus typically infects. Ibalizumab is intended for use in combination with other anti-HIV drugs in people with multi-drug resistant HIV and limited treatment options. This study will collect further information on the safety and tolerability of intravenously administered (IV) ibalizumab combined with an optimized background regimen for treating multi-drug resistant HIV-1 infection, and will provide continuing access to ibalizumab for patients completing a prior ibalizumab clinical trial.
Primary Outcome
Number of participants with Grade 3/4 adverse events possibly, probably, or definitely due to ibalizumab
Interventions
- DRUG ibalizumab
- DRUG Optimized Background Regimen
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 79 participants |
| Start Date | 2016-03 |
| Est. Completion | 2018-11 |
| Phase | Phase 3 |
What the finished NCT02707861 record still lists
NCT02707861 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 79 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (90% lower).
The record links to 0 conditions, and to 2 interventions - of which ibalizumab is the first listed.
NCT02707861 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02707861 about?
NCT02707861 is a clinical study titled "Ibalizumab Plus Optimized Background Regimen in Treatment-Experienced Patients With Multi-Drug Resistant HIV-1". Ibalizumab is a monoclonal antibody that works by blocking HIV entry into the immune system cells (CD4+ or T-cells) the virus typically infects. Ibalizumab is intended for use in combination with other anti-HIV drugs in people with multi-drug resistant HIV and limited treatment options. This study w...
What is the current status of trial NCT02707861?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 79 participants. The study started on 2016-03. Estimated completion is 2018-11.
What interventions are being tested in trial NCT02707861?
The interventions under investigation include: ibalizumab (DRUG), Optimized Background Regimen (DRUG).
Who is sponsoring clinical trial NCT02707861?
This trial is sponsored by TaiMed Biologics, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02707861's enrollment target sits among peer trials
79 1768th of 2000 higher than 232 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05798897 · 79 participants · Phase 1
Safety and Preliminary Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma
- NCT06042439 · 79 participants · NA
AM vs PM Exercise Training
- NCT06223555 · 79 participants · NA
Variability In Mixed Meal Tests: Fixed Versus Adjusted to Energy Needs Caloric Dose
- NCT01243931 · 80 participants · NA
Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia